News
ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide
ChromaDex launches new research tools for the CBD industry with line of reference standardsLOS ANGELES, Feb. 03, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) today announced the expansion of its industry-leading reference standards business with a new line of cannabinoid...
ChromaDex Achieves New Regulatory Milestones in the European Union & Australia
ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivityLOS ANGELES, Jan. 15, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) today announced regulatory authorizations to...
First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex's novel form of vitamin B3LOS ANGELES, Jan. 06, 2020 -- ChromaDex Corp. (NASDAQ:CDXC), the global scientific authority on...
ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®
LOS ANGELES, Dec. 16, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded ChromaDex the 2019 "Best of Industry Award," in the "Ingredient Supplier" category, for...
ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide
Tru Niagen® Pro 500 to be distributed exclusively through licensed healthcare practitionersLOS ANGELES, Dec. 11, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of Tru Niagen® Pro 500, the largest daily serving of its patented nicotinamide...
ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New Zealand
ChromaDex and Matakana Health commit to continued sales growth in Oceania, following approval from Australian regulatory bodyLOS ANGELES, Dec. 05, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with Matakana Health (MHL) until...
ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA)
ChromaDex advances in regulatory process for its patented nicotinamide riboside chloride (NR) ingredient in Australia; receives market exclusivity for two yearsLOS ANGELES, Dec. 02, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) today announced that it has received approval...
European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food
ChromaDex achieves milestone for the launch of nicotinamide riboside in EuropeLOS ANGELES, Nov. 20, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) today announced that European Member States have voted in favor of listing Nicotinamide Riboside Chloride (NR) as a novel food...
ChromaDex Corporation Reports Third Quarter 2019 Financial Results
Third Quarter 2019 Highlights vs. Third Quarter 2018 Strong growth in net sales to $12.1 million, improved gross margin, and significantly improved marketing efficiency year-over-year.TRU NIAGEN net sales of $9.7 million, an 11% increase sequentially and an 86%...
ChromaDex to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
LOS ANGELES, Nov. 04, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Nov. 12, 2019 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2019. The financial results will be reported in a...